Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought.
WSJ.com: WSJD, Wall Street Journal: Technology
Mon, 07/16/2018 - 8:13pm
Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought.